PresentationGood morning, and welcome to Enanta Pharmaceuticals Conference Call. [Operator Instructions] Please be advised that this call is being recorded. I would now like to turn the call over to Jennifer Viera, Head of Investor Relations. Please go ahead.Jennifer VieraExecutive Director of Investor Relations & Corporate Communications Thank you, operator, and thanks to everyone for joining us this morning. The news release announcing the top line results of our RSVHR study became available earlier this ...

Financial Performance - Zoomcar recorded a Contribution Profit of $425 million for the year ended March 31, 2025, compared to a loss of $098 million in the previous year[8] - The company's Contribution Profit as a percentage of Revenue was 47% in FY 2025, a significant improvement from -10% in FY 2024[19, 25] - Zoomcar's Loss from Operations improved by 67%, from -$3167 million in FY 2024 to -$1040 million in FY 2025[19] - Adjusted EBITDA improved by 44%, from -$1785 million in FY 2024 to -$991 million in FY 2025[19, 27] Operational Metrics - Total Bookings increased by 10%, from 387,821 in FY 2024 to 426,788 in FY 2025[10, 19, 27] - Repeat users increased to 13% in FY 2025, compared to 7% in FY 2024[10, 27] - The share of high-quality hosts (with a rating of 45 or higher) increased to 49% in September 2024, compared to 31% in FY 2024[9, 27] - Gross Booking Value (GBV) decreased by 5%, from $2672 million in FY 2024 to $2528 million in FY 2025[19] Fundraising and Debt Restructuring - Zoomcar raised $165 million in Fiscal Year ending March 31, 2025, primarily used for debt repayment and funding growth[16] - The company is in the process of raising additional capital in Fiscal Year ending March 31, 2026, and continues to restructure existing debt to reduce the burden on the balance sheet[16]